<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466255</url>
  </required_header>
  <id_info>
    <org_study_id>DMED-1927-16</org_study_id>
    <secondary_id>CG#17006</secondary_id>
    <secondary_id>ER15-11-029</secondary_id>
    <nct_id>NCT03466255</nct_id>
  </id_info>
  <brief_title>Early Detection of Cardiovascular Disease</brief_title>
  <acronym>VIBE</acronym>
  <official_title>Vascular Imaging as a Barometer for the Early Detection of Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Amer Johri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lantheus Medical Imaging, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to evaluate the correlation between carotid plaque enhancement on
      Contrast-enhanced ultrasound (CEUS), significant coronary artery disease (CAD), and
      cardiovascular (CV) outcomes in a systematic manner. The investigators hypothesize that
      increased levels of CEUS-detected vulnerable carotid plaque will be predictive of CV risk
      determined by angiography and future cardiovascular events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: The investigators will conduct a prospective, single-center, observational
      study at the Cardiovascular Imaging Network at Queen's (CINQ, www.CINQLab.com). This facility
      allows a CEUS protocol to be conducted on the same day as the angiogram. It is anticipated
      that 100 participants can be recruited per month with a total target enrolment of up to 1000
      participants.

      Objectives

        1. To determine the test characteristics (sensitivity, specificity, negative/positive
           predictive values) of carotid plaque by CEUS (Definity(R)) for predicting significant
           CAD (â‰¥50% stenosis) in participants referred for angiography

        2. To determine the test characteristics (sensitivity, specificity, predictive values) of
           carotid plaque by CEUS for predicting future CV events, such as death, stroke,
           myocardial infarction, and cardiovascular interventions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2016</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plaque Height (physiological parameter)</measure>
    <time_frame>4 years</time_frame>
    <description>Caliper measurement of carotid plaque height on ultrasound images, using GE EchoPAC software. The maximum height of either side will be used to correlate to severity of angiographic CAD and neovascularization score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Plaque Area (physiological parameter)</measure>
    <time_frame>4 years</time_frame>
    <description>Area measurement of carotid plaque on ultrasound images (right + left side), using GE EchoPAC software. The total plaque area will be used to correlate to severity of angiographic CAD and neovascularization score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neovascularization (contrast enhancement intensity) (physiological parameter)</measure>
    <time_frame>4 years</time_frame>
    <description>A neovascularization score will be used to grade the &quot;activity&quot; of the carotid plaque per participants and be correlated to angiographic CAD, visualized and manually counted using GE EchoPAC software.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contrast wash-in time (physiological parameter)</measure>
    <time_frame>4 years</time_frame>
    <description>Time of contrast entering the plaque will be assessed to see if it correlates to severity of angiographic CAD, using GE EchoPAC software.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants CV outcome follow-up (data linkage through the Institute for Clinical Evaluative Sciences: ICES)</measure>
    <time_frame>5 years</time_frame>
    <description>Participants will be followed for major adverse cardiac event over 5 years. Number of events will be correlated to carotid plaque measurements.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Atheroma</condition>
  <condition>Cardiac Disease</condition>
  <condition>Vascular Diseases</condition>
  <condition>Atherosclerosis</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Cardiac outpatients</arm_group_label>
    <description>Subjects referred for outpatient coronary angiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Contrast-enhanced ultrasound (CEUS)</description>
    <arm_group_label>Cardiac outpatients</arm_group_label>
    <other_name>Contrast injection - Definity(R)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects referred for outpatient coronary angiography will be screened for inclusion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. &gt;18 years of age

          2. Outpatients referred for clinically indicated angiography for assessment of CAD

          3. Low - Intermediate Framingham risk (&lt;20%)

          4. Absence of clinical contraindication to angiography

          5. Able and willing to give informed consent

        Exclusion criteria:

          1. Patients presenting with acute coronary syndrome

          2. Patients with previously known significant CAD (any lesion &gt;50%) or percutaneous
             coronary intervention or coronary artery bypass surgery

          3. Previous carotid surgery or angioplasty

          4. Documented allergy to echo contrast
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amer M Johri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-France M Hetu, PhD</last_name>
    <phone>613-549-6666</phone>
    <phone_ext>8174</phone_ext>
    <email>cinq.research@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Mantella, MSc</last_name>
    <phone>613-549-6666</phone>
    <phone_ext>8179</phone_ext>
    <email>lauraevemantella@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen's University, Cardiovascular Imaging Network at Queen's (CINQ), Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3N6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amer M Johri, MD</last_name>
      <email>amerschedule@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Amer M Johri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.cinqlab.com</url>
    <description>Cardiovascular Imaging Network at Queen's</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Amer Johri</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

